SCHEMBL4829995

SCHEMBL4829995

CC(C)Oc1ccccc1C1CCN(CCC2c3ccccc3CCN2C(=O)C2CCCCCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.50
ALDH1A1 P00352 1/20 0.50
MTNR1B P49286 4/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PRMT5 O14744 3/20 0.41
WDR77 Q9BQA1 2/20 0.41
KEAP1 Q14145 4/20 0.39
DRD2 P14416 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
KCNH2 Q12809 1/20 0.38
NFE2L2 Q16236 2/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4835975 0.83 NPSR1 (0.57) NPSR1ALDH1A1MTNR1BKEAP1NFE2L2
SCHEMBL4835870 0.83 NPSR1 (0.51) NPSR1ALDH1A1MTNR1BKEAP1CYP2D6
SCHEMBL4833495 0.82 ALDH1A1 (0.55) NPSR1ALDH1A1MTNR1BKEAP1NFE2L2
SCHEMBL4835911 0.82 NPSR1 (0.49) NPSR1ALDH1A1MTNR1BKEAP1NFE2L2
SCHEMBL4836850 0.80 NPSR1 (0.53) NPSR1ALDH1A1MTNR1BMEN1KMT2A
SCHEMBL4838819 0.80 NPSR1 (0.53) NPSR1ALDH1A1MTNR1BMEN1KMT2A
SCHEMBL4839198 0.80 ALDH1A1 (0.51) NPSR1ALDH1A1MTNR1BKEAP1NFE2L2
SCHEMBL4830065 0.80 NPSR1 (0.51) NPSR1ALDH1A1MTNR1BKEAP1DRD2
SCHEMBL4839157 0.79 ALDH1A1 (0.52) NPSR1ALDH1A1MTNR1BMEN1KMT2A
SCHEMBL4836909 0.79 NPSR1 (0.49) NPSR1ALDH1A1MTNR1BKEAP1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 NPSR1 167/4885ALDH1A1 639/4885MTNR1B 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.